91 related articles for article (PubMed ID: 15207005)
1. A simple computer program for calculating PSA recurrence in prostate cancer patients.
Liao Z; Datta MW
BMC Urol; 2004 Jun; 4():8. PubMed ID: 15207005
[TBL] [Abstract][Full Text] [Related]
2. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
4. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
Pauler DK; Finkelstein DM
Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
[TBL] [Abstract][Full Text] [Related]
5. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy.
Taylor JA; Koff SG; Dauser DA; McLeod DG
BJU Int; 2006 Sep; 98(3):540-3. PubMed ID: 16925750
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
7. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
[TBL] [Abstract][Full Text] [Related]
9. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.
Nakagawa T; Kollmeyer TM; Morlan BW; Anderson SK; Bergstralh EJ; Davis BJ; Asmann YW; Klee GG; Ballman KV; Jenkins RB
PLoS One; 2008; 3(5):e2318. PubMed ID: 18846227
[TBL] [Abstract][Full Text] [Related]
10. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
11. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
[TBL] [Abstract][Full Text] [Related]
12. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.
Silverman JM; Krebs TL
AJR Am J Roentgenol; 1997 Feb; 168(2):379-85. PubMed ID: 9016212
[TBL] [Abstract][Full Text] [Related]
13. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
[TBL] [Abstract][Full Text] [Related]
14. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation.
Schaefer U; Witt F; Schueller P; Micke O; Willich N
Anticancer Res; 2000; 20(6D):4989-92. PubMed ID: 11326654
[TBL] [Abstract][Full Text] [Related]
16. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?
Thompson A; Keyes M; Pickles T; Palma D; Moravan V; Spadinger I; Lapointe V; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):415-21. PubMed ID: 20133083
[TBL] [Abstract][Full Text] [Related]
19. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
[TBL] [Abstract][Full Text] [Related]
20. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
